The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group.

SINCE 1964, all the efforts of the Lymphoma Group of the EORTC (European Organisation for Research and Treatment of Cancer) have been devoted to the task of tailoring treatment to the presentation of Hodgkin’s disease (HD) for any given patient [l-12]. We will first briefly review the results of the four controlled studies conducted by the group from 1964 to 1988 for stages I and II HD. We will then present in detail the designs of the on-going H7 randomised trials for these same subsets of Hodgkin’s disease patients.

[1]  C. Haanen,et al.  Major complications and causes of death in patients treated for Hodgkin's disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Noordijk,et al.  Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Horning,et al.  Female Reproductive Potential after Treatment for Hodgkin's Disease , 1981, The New England journal of medicine.

[4]  S. Rosenberg.  Exploratory laparotomy and splenectomy for Hodgkin's disease: a commentary. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Tubiana,et al.  Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Tucker,et al.  Risk of second cancers after treatment for Hodgkin's disease. , 1988, The New England journal of medicine.

[7]  M. Tubiana,et al.  Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[8]  H. Hansen,et al.  RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy , 1987, The Lancet.

[9]  M. Gospodarowicz,et al.  Results of treating Hodgkin's disease without a policy of laparotomy staging. , 1982, Cancer treatment reports.

[10]  E. Noordijk,et al.  Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: emphasis on the role of exploratory laparotomy and fractionation. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  E. Jaffe,et al.  Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Flavio Crippa,et al.  Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Szasz.  Bad habits are not diseases. A refutation of the claim that alcoholism is a disease. , 1972, The Lancet.

[14]  M. Tubiana,et al.  Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease , 1984, Cancer.

[15]  M. Tubiana,et al.  The contribution of clinical trials to the treatment of patients with early stages of Hodgkin's disease. , 1986, Drugs under experimental and clinical research.

[16]  A. Santoro,et al.  Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. , 1986, Annals of internal medicine.

[17]  The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. , 1985 .

[18]  E. Noordijk,et al.  Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. , 1990, International journal of radiation oncology, biology, physics.

[19]  M. Gospodarowicz,et al.  Prognostic groups for management of localized Hodgkin's disease. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Bloomfield,et al.  Hodgkin's disease: a reassessment of prognostic factors following modification of radiotherapy. , 1987, International journal of radiation oncology, biology, physics.

[21]  J. Connors,et al.  An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. , 1988, Seminars in hematology.

[22]  R. Hoppe.  The contemporary management of Hodgkin disease. , 1988, Radiology.

[23]  M. Henry-Amar.  Quantitative risk of second cancer in patients in first complete remission from early stages of Hodgkin's disease. , 1988, NCI monographs : a publication of the National Cancer Institute.

[24]  M. Tubiana,et al.  Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease. , 1981, European journal of cancer.

[25]  M. Tubiana,et al.  A multivariate analysis of prognostic factors in early stage Hodgkin's disease. , 1985, International journal of radiation oncology, biology, physics.

[26]  W. Velasquez,et al.  Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Diehl,et al.  New Aspects in the Diagnosis and Treatment of Hodgkin’s Disease , 1989, Recent Results in Cancer Research.

[28]  A. Horwich,et al.  An analysis of prognostic factors in early stage Hodgkin's disease. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  J. Connors,et al.  MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease. , 1987, Seminars in hematology.

[30]  S. Hancock,et al.  Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. , 1988, Annals of internal medicine.

[31]  Rosenberg Sa,et al.  The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease. , 1985 .

[32]  E. Noordijk,et al.  Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. , 1989 .

[33]  M. Henry-Amar,et al.  Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. , 1990, Seminars in oncology.

[34]  J. Cosset,et al.  Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience , 1991 .

[35]  A. Santoro,et al.  Treatment strategies for Hodgkin's disease. , 1988, Seminars in hematology.

[36]  N. Day,et al.  Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.

[37]  M. Tubiana,et al.  The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy. , 1984, International journal of radiation oncology, biology, physics.